Clinical Trial Update: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A phase 3 trial assessed adding daratumumab to bortezomib and dexamethasone in relapsed or refractory multiple myeloma; results from the study were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2017-02-10